Patents by Inventor Sergei Gryaznov

Sergei Gryaznov has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7321029
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2?-arabino-fluoronucleoside and an internucleoside 3?-NH—P(—O)(OR)—O-5? linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2?-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
    Type: Grant
    Filed: January 19, 2001
    Date of Patent: January 22, 2008
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Ronald G. Schultz
  • Publication number: 20070275919
    Abstract: The present disclosure relates to RNA amidates and thioamidates useful for RNA interference applications. The RNA amidates and thioamidates contain at least one internucleoside linkage chosen from ribo-N3??P5? phosphoramidate (NP) and ribo-N3??P5? thiophosphoramidate (NPS) linkages, and optionally further containing at least one covalently conjugated lipid moiety. Compositions comprising the amidates and thioamidates are disclosed, as are methods for their use in modulating gene expression.
    Type: Application
    Filed: November 3, 2004
    Publication date: November 29, 2007
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20070037770
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3?-NHP(O)(S?)O-5? linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3??P5? phosphoramidates and to exhibit a much higher acid stability.
    Type: Application
    Filed: October 25, 2006
    Publication date: February 15, 2007
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Tracy Matray
  • Patent number: 7138383
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3?-NHP(O)(S?)O-5? linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3??P5? phosphoramidates and to exhibit a much higher acid stability.
    Type: Grant
    Filed: October 18, 2004
    Date of Patent: November 21, 2006
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Tracy Matray
  • Publication number: 20060009636
    Abstract: Orthogonally protected 3?-amino nucleoside monomers and efficient methods for their synthesis are described. The methods employ selective protection of the 3?-amino group in the presence of the unprotected nucleoside base.
    Type: Application
    Filed: June 30, 2005
    Publication date: January 12, 2006
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Daria Zielinska
  • Publication number: 20050113325
    Abstract: Compounds comprising an oligonucleotide moiety covalently linked to a lipid moiety are disclosed. The oligonucleotide moiety comprises a sequence that is complementary to the RNA component of human telomerase. The compounds inhibit telomerase activity in cells with a high potency and have superior cellular uptake characteristics.
    Type: Application
    Filed: September 9, 2004
    Publication date: May 26, 2005
    Inventors: Sergei Gryaznov, Krisztina Pongracz
  • Publication number: 20050049408
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3?-NHP(O)(S?)O-5? linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3??P5? phosphoramidates and to exhibit a much higher acid stability.
    Type: Application
    Filed: October 18, 2004
    Publication date: March 3, 2005
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Tracy Matray
  • Patent number: 6835826
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3′-NHP(O)(S−)O-5′ linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3′→P5′ phosphoramidates and to exhibit a much higher acid stability.
    Type: Grant
    Filed: June 17, 2003
    Date of Patent: December 28, 2004
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Tracy Matray
  • Publication number: 20040126752
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one 2′-arabino-fluoronucleoside and an internucleoside 3′-NH—P(—O)(OR)—O-5′ linkage, where R is a positively charged counter ion or hydrogen, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive phosphoramidate 2′-arabino-fluorooligonucleotides have a high RNA binding affinity to complementary nucleic acids and are base and acid stable.
    Type: Application
    Filed: May 29, 2003
    Publication date: July 1, 2004
    Inventors: Sergei Gryaznov, Ronald G. Schultz
  • Publication number: 20030212032
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3′-NHP(O)(S−)O-5′ linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3′→P5′ phosphoramidates and to exhibit a much higher acid stability.
    Type: Application
    Filed: June 17, 2003
    Publication date: November 13, 2003
    Applicant: GERON CORPORATION
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Tracy Matray
  • Patent number: 6608036
    Abstract: Oligonucleotides with a novel sugar-phosphate backbone containing at least one internucleoside 3′-NHP(O)(S−)O-5′ linkage, and methods of synthesizing and using the inventive oligonucleotides are provided. The inventive thiophosphoramidate oligonucleotides were found to retain the high RNA binding affinity of the parent oligonucleotide N3′→P5′ phosphoramidates and to exhibit a much higher acid stability.
    Type: Grant
    Filed: September 8, 2000
    Date of Patent: August 19, 2003
    Assignee: Geron Corporation
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Tracy Matray
  • Publication number: 20030138814
    Abstract: Oligonucleotide conjugates, where an oligonucleotide is covalently attached to an aromatic system, are provided. In particular embodiments the oligonucleotide is complementary to the RNA component of human telomerase and is covalently attached to a nucleobase via an optional linker. The conjugates inhibit telomerase enzyme activity.
    Type: Application
    Filed: September 25, 2002
    Publication date: July 24, 2003
    Inventors: Sergei Gryaznov, Krisztina Pongracz, Gregg B. Morin, Richard L. Tolman
  • Patent number: 5684143
    Abstract: A new class of oligonucleotide N3'.fwdarw.P5' phosphoramidates having 2' fluoro substituents are provided that have superior acid stability. The invention includes oligo-2'-fluoronucleotide N3'.fwdarw.P5' phosphoramidates, methods of synthesis, and duplexes and triplexes formed with DNA and RNA. Compounds of the invention are useful where the formation of stable and specific duplex and/or triplex structures is desired, including antisense and/or anti-gene pharmaceuticals, branched DNA components, DNA and/or RNA capture agents, components of DNA-based diagnostic assays, and the like.
    Type: Grant
    Filed: February 21, 1996
    Date of Patent: November 4, 1997
    Assignee: Lynx Therapeutics, Inc.
    Inventors: Sergei Gryaznov, Ronald G. Schultz